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Hong Kong
Objectives. This study sought to examine the effect of mitral
regurgitation (MR) on platelet activation in patients with mitral
valve prolapse (MVP) or rheumatic MR.
Background. MVP and rheumatic MR are associated with an
increased incidence of thromboembolic events. Although the un-
derlying causes are not clear, increased platelet activation has
been suggested as one of the pathogenic mechanisms. Results of
previous studies that have investigated the relation between MVP
and platelet activation are controversial. Whether the presence of
MR in patients with mitral valve disease is associated with
platelet activation remains unclear.
Methods. We studied platelet activation by measuring the
plasma level of platelet factor 4 (PF4) and beta-thromboglobulin
(BTG) in 16 patients with MVP, 12 patients with rheumatic MR
and 25 control subjects. A detailed echocardiographic examina-
tion, including M-mode measurement and color Doppler flow
mapping to detect the presence and severity of MR was performed.
Results. Patients and control subjects were matched for gender,
age and left ventricular ejection fraction. Eight (50%) of 16
patients with MVP had MR. Patients with MVP and MR and
patients with rheumatic MR had a significantly larger left atrial
diameter. Mean log plasma levels of PF4 and BTG were signifi-
cantly higher in patients with MVP and MR and patients with
rheumatic MR than in control subjects (1.17 6 0.22 and 0.93 6
0.23 IU/ml vs. 0.52 6 0.34 IU/ml, p < 0.01; 1.70 6 0.21 and 1.53 6
0.15 IU/ml vs. 1.37 6 0.15 IU/ml, p < 0.05, respectively) but were
comparable in patients with MVP and no MR and control
subjects. Plasma levels of PF4 and BTG were positively correlated
with the severity of MR, as assessed by a semiquantitative method
(r 5 0.59, p 5 0.0001; r 5 0.60, p 5 0.0001, respectively).
Increasing age and left atrial enlargement were not related to
platelet activation.
Conclusions. MR in mitral valve disease was associated with
systemic platelet activation. MVP itself was not associated with
increased platelet activation. The degree of platelet activation was
positively correlated with the severity of MR and was independent
of the underlying etiology of mitral valve disease, age and left
atrial size. The possibility of a higher incidence of thromboembo-
lism and the role of antiplatelet agents in such patients will
require further studies to determine.
(J Am Coll Cardiol 1997;30:1813–8)
©1997 by the American College of Cardiology
Mitral valve prolapse (MVP) is the most common valvular
heart disease and has a prevalence of 3% to 4% in the general
population (1–5). Although the long-term prognosis of MVP is
usually benign, thromboembolic complications, including cere-
bral and retinal ischemic events, may occur (6–11). Previous
studies (6,8) have demonstrated a fourfold to sixfold higher
incidence of MVP in young patients with cerebral ischemia
than in age-matched control subjects. The etiology of increas-
ing thromboembolic events in patients with MVP is unknown.
It has been suggested (12) that these events may be related to
platelet activation due to exposure to an abnormal valvular
surface or hemodynamic irregularity. However, previous stud-
ies (13–19) that have investigated platelet activation in patients
with MVP have yielded controversial results. The broad spec-
trum of patients with MVP probably explains the different
results obtained in studies of platelet activation. Patients with
MVP are heterogeneous with regard to left atrial size and the
presence or absence and severity of mitral regurgitation (MR).
The thromboembolic risk of patients with rheumatic MR is
also increased and is higher in those with severe MR (20,21).
Whether MR in MVP may result in platelet activation and,
subsequently, an increased risk of thromboembolism is un-
clear. The purpose of the present study was to determine the
significance of MR on platelet activation by evaluating two
markers of platelet activation in patients with MVP or rheu-
matic MR.
Methods
Study patients. The study included 16 patients (4 men, 12
women; mean [6SD] age 44 6 12 years) with echocardio-
graphically documented MVP and 12 (4 men, 8 women; mean
age 44 6 12 years) with a previous history of acute rheumatic
fever and echocardiographically documented rheumatic MR
without significant mitral stenosis (mean mitral valve area
3.2 6 0.3 cm2). These patients were consecutive outpatients
seen at our cardiac clinic for asymptomatic cardiac murmur (18
[64%] of 28) or nonspecific complaints, such as palpitations or
atypical chest pain (4 [36%] of 12). The control group included
25 subjects (10 men, 15 women; mean age 40 6 11 years), all
of whom had normal findings on physical examination, rest
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electrocardiography and echocardiography. Neither patients
nor control subjects had a history of coronary artery disease,
cerebrovascular disease, peripheral vascular disease, diabetic
mellitus, cancer, renal failure, deep vein thrombosis or pulmo-
nary embolism, which are known to be associated with platelet
activation (22). Furthermore, patients with previously docu-
mented severe MR, other coexisting valvular lesions or atrial
tachyarrhythmia were also excluded. The study protocol was in
agreement with the guidelines approved by the ethics commit-
tee of our local institution.
Echocardiographic study. Two-dimensional (2D), M-
mode and color Doppler transthoracic echocardiographic
studies were performed in all subjects (Acuson, model 128XP
10C, 2.5/3.5-MHz probe). The echocardiographic examina-
tions were performed by an experienced technician and were
reviewed in blinded manner by two physicians (H.-F.T., C.-
P.L.). Two-dimensional parasternal long-axis, short-axis and
apical four-chamber views were recorded to visualize the
anterior and posterior mitral leaflets adequately. M-mode
echocardiography was performed according to the recommen-
dations of the American Society of Echocardiography (23).
Mitral valve area was also measured by the pressure half-time
method (24). Color Doppler was used to detect the presence of
MR, and MR severity was assessed by a semiquantitative
method. We measured the percent ratio of the maximal flow
disturbance produced by the MR jet to the left atrial area and
graded it according to the Nagle criteria (angiographic) as
follows: 1) ,20% was considered mild; 2) 20%–40% was
graded as moderate; and 3) .40% was considered severe (24).
MVP was diagnosed when the apposed mitral leaflets were
displaced posterior to the C-D line $2 mm in late systole or
$3 mm for holosystolic MVP on M-mode echocardiography.
Holosystolic M-mode MVP was accepted only if confirmed by
leaflet billowing into the left atrium on the parasternal or
apical long-axis views (1,25–27). Rheumatic MR was diagnosed
when the mitral leaflets were thickened and calcified and had
evidence of fusion of mitral commissures or subvalvular appa-
ratus on 2D examination and when MR was present on color
Doppler (24,28).
Platelet activation study. Platelet activation was assessed
by measuring both plasma levels of platelet factor 4 (PF4)
and beta-thromboglobulin (BTG). Both are platelet-specific
proteins secreted from the alpha-granules during the release
reaction (22,29). These proteins can be accurately measured
by enzyme-linked immunosorbent assay (ELISA), provided
that special precautions (see later) are taken to prevent in vitro
activation during phlebotomy and plasma processing (29).
We measured both PF4 and BTG levels to assess in vivo
platelet activation. High levels of BTG in the presence of
normal or only slightly elevated levels of PF4 strongly sug-
gest in vivo release, whereas comparable elevations in both
suggest in vitro release. The ratio of BTG to PF4 was used to
exclude in vitro activation; a significant increase in ratio (.3)
suggested in vivo activation (30,31). Blood results with evi-
dence of in vitro platelet activation (BTG/PF4 ratio ,3:1) were
not included for analysis.
Patients and control subjects were instructed to abstain
from any medication or alcohol for 10 days before blood
sampling. All blood samples were taken in the morning for
convenience in processing. Precautions were taken to avoid ex
vivo activation of platelet. Blood samples were drawn by
venipuncture using a 21-gauge indwelling butterfly needle
without the use of a tourniquet. The first 2 ml of blood was
discarded, and the next 4 to 5 ml of blood was collected into a
Diatube H tube (Diagnostic Stago, France) that was immedi-
ately placed in an icewater bath for at least 15 min and then
centrifuged at 2,500g for 30 min at 4°C. After centrifugation,
approximately one-third the volume of the plasma supernatant
was collected by placing the pipette tip in the middle region of
the supernatant to avoid aspirating any light platelets found at
the top surface of the plasma and platelets resting on the top
surface of the cell layer. The platelet-poor plasma was stored at
220°C. PF4 and BTG assays were carried out within 1 month
of collection of the sample.
PF4 and BTG assays. PF4 and BTG determinations were
performed by ELISA using a commercially available kit (As-
serachrom PF4 and BTG, Diagnostica Stago) according to the
manufacturer’s instructions. Specific rabbit anti-human PF4
and BTG antibodies and anti-PF4- and anti-BTG-peroxidase
conjugates were used. PF4 and BTG concentrations were
determined from a PF4 and BTG absorbency calibration curve.
Both PF4 and BTG assays were run with the same positive
controls each time for calibration, and the results were highly
reproducible (.95%). One-third of the patients’ samples were
run in duplicate and the results were again comparable.
Statistical methods. Results are expressed as mean
value 6 SD. Plasma levels of BTG and PF4 are logarithmically
distributed; thus, log-transformed data were used for analysis
(29). Differences in continuous variables were analyzed by
paired or unpaired Student t tests or analysis of variance, as
appropriate, and between-group comparisons were performed
by multiple Bonferroni tests. Correlation between variables
was determined by linear regression, with severity of MR
converted to an ordinal scale (1–3). A p value ,0.05 was
considered significant.
Results
Clinical characteristics and echocardiographic variables
(Table 1). The study groups were matched for age, gender and
left ventricular ejection fraction. Eight patients with MVP
Abbreviations and Acronyms
ANOVA 5 analysis of variance
BTG 5 beta-thromboglobulin
ELISA 5 enzyme-linked immunosorbent assay
MR 5 mitral regurgitation
MVP 5 mitral valve prolapse
PF4 5 platelet factor 4
2D 5 two-dimensional
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(50%) and all patients with rheumatic MR (100%) had MR
detected by color Doppler. Using the color Doppler semiquan-
titative method, three and five patients with MVP had mild and
moderate MR, respectively, and nine and three patients with
rheumatic MR had mild and moderate MR, respectively. In
each subgroup of patients with mild or moderate MR, there
was no significant difference in percent ratio of mitral regur-
gitant area/left atrial area between patients with MVP or
rheumatic MR.
Left atrial diameter was significantly larger in patients with
MVP and those with rheumatic MR than in control subjects.
However, subgroup analysis showed that only patients with
MVP with MR had left atrial enlargement. A modest but
significant positive correlation was observed between left atrial
diameter and severity of MR (r 5 0.42, p 5 0.0019) (Fig. 1).
Platelet activation study. Mean log plasma levels of PF4
and BTG were significantly higher in patients with MVP and in
those with rheumatic MR than in control subjects (0.94 6 0.38
and 0.93 6 0.23 IU/ml vs. 0.52 6 0.34 IU/ml, p , 0.01; 1.56 6
0.24 and 1.53 6 0.15 IU/ml vs. 1.37 6 0.15 IU/ml, p , 0.05,
respectively) (Fig. 2).
Significance of MR in MVP. Subgroup analysis showed that
plasma levels of PF4 and BTG were significantly increased only
in patients with MVP with MR compared with control group
values (1.17 6 0.22 vs. 0.52 6 0.34 IU/ml, p , 0.001; 1.70 6
0.21 vs. 1.37 6 0.15 IU/ml, p , 0.001, respectively). PF4 and
BTG levels were comparable in patients with MVP without
MR and control subjects. Furthermore, patients with MVP
with MR also had significantly higher plasma levels of PF4 and
BTG than those with MVP without MR (1.17 6 0.22 vs. 0.71 6
Figure 1. Relation between left atrial (LA) size and severity of MR in
patients with MVP or rheumatic MR (RH.MR) and control subjects.
Solid line 5 fitted regression line; dotted lines 5 95% confidence
limits. Mod. 5 moderate.
Figure 2. Log mean plasma levels of PF4 and BTG in patients with
MVP or rheumatic MR (RH. MR) and control subjects. MR1 5 with
MR; MR2 5 without MR. Top, *p , 0.001, **p , 0.01 versus control
subjects; bottom, *p , 0.01, **p , 0.05 versus control subjects.
























Age (yr) 40 6 10.9 43.8 6 11.9 0.274 47.0 6 9.7 0.098 40.5 6 13.6 0.851 44.4 6 12.1 0.307
Men/women 10/15 4/12 0.501 2/6 0.678 2/6 0.678 4/8 0.99
LVEF (%) 60.2 6 7.9 64.6 6 8.0 0.086 65.5 6 8.0 0.219 63.8 6 8.5 0.143 63.0 6 7.0 0.294
LA (mm) 29.1 6 7.6 34.8 6 7.9 0.021* 39.8 6 8.0 0.034* 29.8 6 3.6 0.119 35.1 6 6.9 0.0189*
Severity of MR
Mild NA 3 3 NA 9
Ratio (%) 14 6 5 14 6 5 12 6 3
Moderate NA 5 5 NA 3
Ratio (%) 32 6 6 32 6 6 29 6 4
*p , 0.05 versus control subjects. Data presented are mean value 6 SD, number of patients or regurgitant jet area/left atrial area ratio. LA 5 left atrium; LVEF 5
left ventricular ejection fraction; MR 5 mitral regurgitation; NA 5 not applicable.
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0.37 IU/ml, p , 0.05; 1.70 6 0.21 vs. 1.40 6 0.20 IU/ml, p ,
0.01, respectively) (Fig. 2).
Comparison between MVP and rheumatic MR. There was no
significant difference in plasma levels of PF4 and BTG between
patients with MVP and those with rheumatic MR. Patients
with MVP with MR had significantly higher plasma levels of
PF4 and BTG than patients with rheumatic MR (1.17 6 0.22
vs. 0.93 6 0.23 IU/ml, p , 0.05; 1.70 6 0.21 vs. 1.53 6 0.15
IU/ml, p , 0.05, respectively). However, after adjustment for
severity of MR as a covariate, the difference in plasma levels of
PF4 and BTG became insignificant (p . 0.05).
Relation between severity of MR and platelet activation. The
presence of mild or moderate MR was associated with signif-
icantly increased plasma levels of PF4 and BTG (Fig. 3).
Furthermore, a significant positive correlation was observed
between severity of MR (none, mild or moderate) and plasma
levels of PF4 and BTG (r 5 0.59, p 5 0.0001; r 5 0.60, p 5
0.0001, respectively) (Fig. 4).
Other variables and platelet activation. There was no age-
dependence tendency (r 5 0.06, p 5 0.68; r 5 0.16, p 5 0.26,
respectively) and only a weak correlation between left atrial
diameter and plasma levels of PF4 and BTG (r 5 0.38, p 5
0.005; r 5 0.38, p 5 0.005, respectively).
Discussion
Background. Previous studies (5–11,32,33) evaluating the
association between MVP and thromboembolism have yielded
controversial results. Most patients with MVP have a benign
course, but subsets of patients with clinical evidence of MR are
at risk for development of complications (34–37). Patients with
rheumatic MR have at least a medium risk of thromboembo-
lism (38). The incidence of thromboembolism in these patients
is ;1% to 3%/year and is higher in those with severe MR or
associated mitral stenosis (20,21). Thus, the presence of MR
may increase the risk of thromboembolic events in patients
with MVP or rheumatic MR, although the underlying mecha-
nism is still unclear.
Alterations in all phases of hemostasis are associated with
thromboembolic events; however, platelet activation occurs in
the earliest phase of arterial hemostasis and plays an important
role in these disorders. Although a direct causal relation
between platelet activation and thromboembolism is lacking,
previous studies (39,40) have provided supportive evidence for
an association between them. Furthermore, the fact that
antiplatelet agents are efficacious in the secondary prevention
of thromboembolism provides further indirect evidence for
this association (41). Previous studies (12,13,42) showed that
abnormal platelet hyperactivity in patients with rheumatic
mitral valve disease and MVP was associated with thrombo-
embolism, leading to the hypothesis that platelet interaction
with the irregular endocardial surface of the abnormal mitral
valve might give rise to in vivo platelet activation, potentially
resulting in thromboembolic events. However, previous studies
(13–19) investigating platelet activation in MVP showed incon-
sistent results. The broad spectrum of subjects with MVP
probably explains the different results obtained in studies of
platelet activation. Patients with MVP are heterogeneous with
regard to left atrial size, presence or absence of MR and the
severity of MR. However, no study has investigated the
relation between MR and platelet activation in patients with
MVP or valvular heart disease.
Relation between MR and platelet activation in mitral
valve disease. Both PF4 and BTG are specific platelet proteins
that are stored in the alpha-granules and released in plasma
during platelet activation. We found that patients with MVP
and those with rheumatic MR had significantly higher plasma
levels of PF4 and BTG than control subjects, and a subgroup
analysis showed that patients with MVP with MR have signif-
Figure 3. Log mean plasma levels of PF4 and BTG in patients with
mild or moderate (Mod.) MR. *p , 0.05, **p , 0.001 versus no MR.
Figure 4. Relation between plasma levels of PF4 and BTG and
severity of MR in patients with MVP or rheumatic MR (RH.MR) and
control subjects. Mod. 5 moderate. Symbols as in Figure 1.
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icantly elevated plasma PF4 and BTG levels compared with
those without MR and control subjects. MVP itself, without
MR, was not associated with any significant difference in the
levels of markers of platelet activation compared with control
values. This finding may explain the discrepancy between
previous studies on platelet activation in patients with MVP
because the presence of MR was not considered in those
studies. Both mild and moderate MR were associated with
significant elevation in plasma levels of PF4 and BTG. More
important, we demonstrated that severity of MR was positively
correlated to degree of platelet activation. This finding is
consistent with the clinical observation that patients with more
severe MR had a higher incidence of thromboembolic events
(21).
MVP with MR was also associated with significantly more
elevated levels of PF4 and BTG than rheumatic MR and was
related to the discrepancy in the proportion of patients with
different grades of MR severity. The proportion of patients
with moderate MR was higher in patients with MVP than in
those MVP patients with rheumatic MR (63% vs. 25%). When
severity of MR was also taken into consideration, valve disease
etiology was not an independent predictor of increased platelet
activation. Furthermore, the finding of a direct relation be-
tween degree of platelet activation and severity of MR also
supports this observation. The control and study groups were
matched for age and gender, and there was no association
between the age and degree of platelet activation. As expected,
the left atrium was larger in patients with MR, and there was
a modest correlation between severity of MR and left atrial
size. There was only a weak correlation between left atrial size
and platelet activation, which may be related indirectly to MR.
Possible mechanism of platelet activation in MR. In pa-
tients with MVP, the formation of an adherent thrombus at the
cul-de-sac created between the ballooning posterior leaflet and
the atrial wall is usually attributed to a localized jet of MR
(43,44). On cine ventriculograms during diastole, the regurgi-
tant material is observed to swirl briefly into the left atrium and
collect into a posteroinferior cul-de-sac, remaining stagnant
there until the end of diastole (32). Thus, the mechanism of
platelet activation associated with MR may be due to hemo-
dynamic irregularities (turbulent flow in the left atrium)
caused by the regurgitant jet in the presence of an abnormal
valvular surface, independent of the underlying etiology. The
activated platelet may then adhere and aggregate on the
abnormal mitral valvular surface to form a platelet–fibrin
thrombus on the leaflet, potentially resulting in thromboem-
bolic events.
Clinical implications. The present study demonstrated
that MR in patients with MVP or rheumatic MR was associ-
ated with systemic platelet activation. MVP itself was not
associated with increased platelet activation. The degree of
platelet activation was positively correlated with severity of
MR and was independent of the underlying etiology of the
mitral valve disease, age and left atrial size. Hence, both the
presence and severity of MR are important factors that lead to
platelet activation and may be an important pathogenic mech-
anism for the formation of platelet–fibrin thrombi on the
abnormal mitral leaflet, subsequently leading to increased risk
of thromboembolic events in patients with MVP or rheumatic
MR.
Study limitations. Because all our patients had no previous
history of thromboembolic events, we could not demonstrate a
causal relation between platelet activation and thromboem-
bolic events. The interpretation of PF4 and BTG results is
often confounded by methodologic problems due to in vitro
activation of platelet. However, special precautions were taken
to reduce in vitro activation during the procedure, and the
results were checked for evidence of in vitro activation, as
previously described (29,30).
Conclusions. The present study demonstrated that in the
presence of an abnormal mitral valve surface, as in MVP and
rheumatic heart disease, even mild to moderate MR is associ-
ated with platelet activation. Whether these patients have a
higher incidence of thromboembolism and what role antiplate-
let agents play in such patients will require further studies.
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